Inspira Technologies公司今日宣布，已正式获得全球年收入达120亿美元的医疗管理组织供应商资质认证。此项突破性进展意味着，该公司的革命性产品ART100系统将立即启动商业化部署流程。
此次合作方为全球规模第二大的健康维护组织，其庞大的医疗网络覆盖将为ART100系统提供前所未有的临床应用场景。作为尖端血液氧合技术解决方案，ART100系统的快速部署将重塑急性呼吸衰竭患者的治疗范式。
供应商资质的获取不仅打通了Inspira进入主流医疗市场的通道，更标志着其创新技术获得了顶级医疗机构的专业认可。在价值千亿美元的医疗科技赛道中，此举为公司后续拓展全球市场奠定了关键基石。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.